Group 1 - The core viewpoint of the news is the successful financing of Chongqing Hanpei Biotechnology Co., Ltd., which focuses on innovative pet drugs, marking a significant achievement for the Chongqing municipal government's seed fund in supporting early-stage tech projects and facilitating technology transfer [3][4] Group 2 - Chongqing Hanpei Biotechnology was founded in September 2022 and specializes in developing first-in-class and best-in-class innovative drugs for pets, addressing clinical issues such as chronic diseases, gastrointestinal diseases, metabolic disorders, and antibiotic-resistant infections [3] - The company has multiple innovative product pipelines, with one drug for treating pet infections and gastrointestinal diseases having entered clinical trials, showcasing strong technological originality and market potential as there are no competing products with the same target globally [3] Group 3 - The Chongqing Seed Fund, established in 2024, has a total scale of 200 million yuan and is managed by the Chongqing Technology Innovation Investment Group, focusing on early-stage technology projects and startups [4] - As of October 2025, the Chongqing Seed Fund has supported over 60 projects with a total investment of 62.45 million yuan, establishing an effective early project cultivation mechanism [4] - Hanpei Biotechnology is a typical case of this systematic cultivation model, having accelerated its development and achieved recognition as a national high-tech enterprise and an innovative small and medium-sized enterprise [4]
重庆种子基金成效初显 首批项目汉佩生物完成千万元级融资
Sou Hu Cai Jing·2025-12-02 16:54